Aria CV PH system
The FDA granted breakthrough device designation in early February to Aria CV for its pulmonary hypertension (PH) system for treating pulmonary arterial hypertension (PAH) that can lead to heart failure.
The implanted system is designed to restore the benefits of a healthy, elastic pulmonary artery. The restoration should lead to reduced cardiac workload and enhance blood flow, potentially improving both the duration and quality of life.
The PH system has the potential to treat PAH effectively with fewer side effects when compared to the available drug therapies, according to Dr. Gregg Stone, director of academic affairs for Mount Sinai Heart Health System and a member of Aria CV’s scientific advisory board.